The effects of simvastatin on the C-reactive protein level and lipid profile in the acute phase of ischaemic stroke in relation to -717A>G CRP gene polymorphism

Dariusz Kotlęga, Monika Białecka, Mateusz Kurzawski, Marek Droździk, Monika Gołąb-Janowska, Sylwester Ciećwież, Przemysław Nowacki


Introduction: The pathogenesis and risk of ischaemic stroke are associated with the inflammatory process that is involved in the development of atherosclerosis. The blood level of C-reactive protein (CRP) is a widely used predictor of inflammation. The level of this protein is used for the assessment of risk and prognosis in cardiovascular disorders and stroke. C-reactive protein level depends on genetic and environmental factors such as genetic polymorphism and statin use. The aim of the study was to assess the potential effects of simvastatin on the CRP level and lipid profile in stroke in regard to the variant of -717A>G CRP gene polymorphism.

Materials and methods: There were 125 subjects enrolled in the study, hospitalized with a diagnosis of ischaemic stroke (95 patients in group 1 and 30 patients in group 2). Patients in group 1 were treated with a 40 mg dose of simvastatin from the 1st day; in group 2 simvastatin was not used. Blood CRP level and lipid profile were measured in all patients on day 1 and 10 after admission. The -717A>G CRP gene polymorphism status was genotyped in all patients.

Results: In both groups there was a significant increase in CRP level, despite simvastatin treatment. No association was found between genotype and levels of both CRP and lipids change from the 1st to the 10th day.

Conclusions: Simvastatin does not affect the CRP level in relation to any of the -717A>G CRP gene polymorphism variants in the acute phase of stroke. Simvastatin significantly changes lipid levels, but it does not depend on -717A>G CRP gene polymorphism.


stroke; genetic polymorphism; C-reactive protein; lipids; atherosclerosis; statins

Full Text:



Warlow C, Sudlow C, Dennis M, Wardlaw J, Sandercock P. Stroke. Lancet 2003;362:1211-24. doi: 10.1016/S0140-6736(03)14544-8.

Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 2006;37(7):1923-32. doi:10.1161/01.STR.0000226901.34927.10.

Andersson J, Johansson L., Ladenvall P, Wiklund PG, Stegmayr B, Jern C, et al. C-reactive protein is a determinant of first-ever stroke: prospective nested case-referent study. Cerebrovasc Dis. 2009;27(6):544-51. doi: 10.1159/000214217.

Ladenvall C, Jood K, Blomstrand C, Nilsson S, Jern C, Ladenvall P. Serum C-reactive protein concentration and genotype in relation to ischemic stroke subtype. Stroke 2006;37(8):2018-23. doi:10.1161/01.STR.0000231872.86071.68.

Lip GY, Patel JV, Hughes E, Hart RG. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema and prognosis. Stroke 2007;38(4):1229-37. doi: 10.1161/01.STR.0000260090.90508.3e.

Ridker PM, Cuchman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336(14):973-9. doi: 10.1056/NEJM199704033361401.

Schlager O, Exner M, Mlekusch W, Sabeti S, Amighi J, Dick P, et al. C-reactive protein predicts future cardiovascular events in patients with carotid stenosis. Stroke 2007;38(4):1263-8. doi: 10.1161/01.STR.0000259890.18354.d2.

Elkind MS, Coates K, Tai W, Paik MC, Boden-Albala B, Sacco RL. Levels of acute phase proteins remain stable after ischemic stroke. BMC Neurol 2006;6:37. doi: 10.1186/1471-2377-6-37.

Shantikumar S, Grant PJ, Catto AJ, Bamford JM, Carter AM. Elevated C-reactive protein and long-term mortality after ischaemic stroke: relationship with markers of endothelial cell and platelet activation. Stroke 2009;40(3):977-9. doi: 10.1161/STROKEAHA.108.525105.

Welsh P, Lowe GD, Chalmers J, Campbell DJ, Rumley A, Neal BC, et al. Associations of proinflammatory cytokines with the risk of recurrent stroke. Stroke 2008;39(8);2226-30. doi: 10.1161/STROKEAHA.107.504498.

Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 2001;32(4):917-24.

Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischaemic stroke. Arch Intern Med 2006;166(19):2073-80. doi: 10.1001/archinte.166.19.2073.

Montaner J, Fernandez-Cadenas I, Molina CA, Ribó M, Huertas R, Rosell A, et al. Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke 2006;37(5):1205-10.

Morita A, Nakayama T, Soma M. Association study between C-reactive protein genes and ischemic stroke in Japanese subjects. Am J Hypertens 2006;19(6):593-600. doi: 10.1016/j.amjhyper.2005.11.015.

Assayag EB, Shenhar-Tsafaty S, Bova I, Berliner S, Usher S, Peretz H, et al. Association of the -757T>C polymorphism in the CRP gene with circulating C-reactive protein levels and carotid atherosclerosis. Thromb Res 2009;124(4):458-62. doi: 10.1016/j.thromres.2009.04.008.

Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, Rumley A, et al. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol 2003;23(11):2063-9. doi: 10.1161/01.ATV.0000084640.21712.9C.

Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF, et al. Genetic loci influencing C-reactive protein levels and risk of coronary heart disease. JAMA 2009;302(1):37-48. doi: 10.1001/jama.2009.954.

Kathiresan S, Larson MG, Vasan RS, Guo CY, Gona P, Keaney JF, et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006;113(11):1415-23. doi: 10.1161/CIRCULATIONAHA.105.591271.

Kovacs A, Green F, Hansson LO, Lundman P, Samnegard A, Boquist S, et al. A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis 2005;178(1):193-8. doi: 10.1016/j.atherosclerosis.2004.08.018.

Miller DT, Zee RY, Danik JS, Kozlowski P, Chasman DI, Lazarus R, et al. Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet 2005;69:623-38. doi: 10.1111/j.1529-8817.2005.00210.x.

Pai JK, Mukamal KJ, Rexrode KM, Rimm EB. C-reactive protein (CRP) gene polymorphisms, CRP levels, and risk of incident coronary heart disease in two nested case-control studies. PLoS ONE 2008;3(1):e1395. doi: 10.1371/journal.pone.0001395.

Arenillas JF, Massot A, Alvarez-Sabin J, Fernandez-Cadenas I, del Rio-Espinola A, Chacon P, et al. C-reactive protein gene C1444T polymorphism and risk of recurrent ischemic events in patients with symptomatic intracranial atherostenoses. Cerebrovasc Dis 2009;28(1):95-102. doi: 10.1159/000222660.

Assayag EB, Shenhar-Tsarfaty S, Bova I, Berliner S, Shopin L, Peretz H, et al. Triggered C-reactive protein (CRP) concentrations and the CRP gene 717A>G polymorphism in acute stroke or transient ischaemic attack. Eur J Neurol 2007;14(3):315-20. doi: 10.1111/j.1468-1331.2006.01661.x.

Pai JK, Kim OY, Koh SJ, Jang Y, Chae JS, Kim JY, et al. Additive effect of interleukin-6 and C-reactive protein (CRP) single nucleotide polymorphism on serum CRP concentration and other cardiovascular risk factors. Clin Chim Acta 2007;380(1-2):68-74. doi: 10.1016/j.cca.2006.11.011.

Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation 1997;96:4204-10.

Chen J, Zhao J, Huang J, Su S, Qiang B, Gu D. -717A>G polymorhism of human C-reactive gene associated with coronary heart disease in ethnic Han Chinese: the Beijing atherosclerosis study. J Mol Med 2005(1);83:72-8. doi: 10.1007/s00109-004-0585-5.

Wang Q, Ding H, Tang JR, Zhang L, Xu YJ, Yan JT, et al. C-reactive protein polymorphisms and genetic susceptibility to ischemic stroke and hemorrhagic stroke in the Chinese Han population. Acta Pharmacol Sin 2009;30(3):291-8. doi: 10.1038/aps.2009.14.

Wang L, Lu X, Li Y, Chen S, Gu D. Functional analysis of thee C-reactive protein (CRP) gene -717A>G polymorphism associated with coronary heart disease. BMC Med Genet 2009;10:73.

Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107(3):499-511.

Toth PP, Davidson MH. High-dose statin therapy: benefits and safety in aggressive lipid lowering. J Fam Pract 2008;57:S29-36.

Kotlęga D, Ciećwież S, Turowska-Kowalska J, Nowacki P. Pathogenetic justification of statin use in ischaemic stroke prevention according to inflammatory theory in development of atherosclerosis. Neurol Neurochir Pol 2012;46(2):176-83.

Stüve O, Youssef S, Steinman L, Zamvil SS. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol 2003;16(3):393-401. doi: 10.1097/01.wco.0000073942.19076.d1.

Liao JK. Clinical implications for statin pleiotropy. Curr Opin Lipidol 2005;16(6):624-9.

Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004;35(12):2902-9. doi: 10.1161/01.STR.0000147965.52712.fa.

Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-67. doi: 10.1016/S0140-6736(04)


Amarenco P, Bogousslavsky J, Callahan A. 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischaemic attack. N Engl J Med 2006;355(6):549-59. doi: 10.1056/NEJMoa061894.

Kotlęga D, Nowacki P, Białecka M, Kurzawski M, Droździk M, Ciećwież S. Association between CRP gene polymorphism 717A/G, C-reactive protein and neurological deficit in ischaemic stroke. J Clin Neurosci 2014;21:574-7.


Anderson JL, Maycock CA, Lappe DL, Crandall BG, Horne BD, Bair TL, et al. Frequency of elevation of C-reactive protein in atrial fibrillation. Am J Cardiol 2004;94(10):1255-9. doi: 10.1016/j.amjcard.2004.07.108.

Hadi HA, Mahmeed WA, Suwaidi JA, Ellahham S. Pleiotropic effects of statins in atrial fibrillation patients: the evidence. Vasc Health Risk Manag 2009;5(3): 533-51.

Sata N, Hamada N, Horinouchi T, Amitani S, Yamashita T., Mori­yama Y. C-reactive protein and atrial fibrillation. Jpn Heart J 2004;45(3):441-5.

Maas MB, Furie KL. Molecular biomarkers in stroke diagnosis and prognosis. Biomark Med 2009;3(4):363-83. doi: 10.2217/bmm.09.30.

Li JJ, Wang Y, Nie SP, Zhang CY, Li YS, Hui RT, et al. Reduction of C-reactive protein by a single 80 mg of simvastatin in patients with unstable angina. Clin Chim Acta 2007;376:163-7. doi: 10.1016/j.cca.2006.08.012.

Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577-81.

Li JJ, Chen MZ, Chen X, Fang CH. Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia. Clin Cardiol 2003;26(10):472-6.

Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105(9):1135-43.

Akbarzadeh NR, Ghaderian SM, Tabatabaei Panah AS. C-reactive protein (CRP) gene polymorphisms: implication in CRP plasma levels and susceptibility to acute myocardial infarction. Mol Biol Rep 2012;39(4): 3705-12. doi: 10.1007/s11033-011-1145-z.


Copyright (c) 2017

License URL: